Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Targeted regulation of TAK1 counteracts dystrophinopathy in a DMD mouse model
Anirban Roy, … , Mingfu Wu, Ashok Kumar
Anirban Roy, … , Mingfu Wu, Ashok Kumar
Published April 18, 2023
Citation Information: JCI Insight. 2023;8(10):e164768. https://doi.org/10.1172/jci.insight.164768.
View: Text | PDF
Research Article Muscle biology Therapeutics

Targeted regulation of TAK1 counteracts dystrophinopathy in a DMD mouse model

  • Text
  • PDF
Abstract

Muscular dystrophies make up a group of genetic neuromuscular disorders that involve severe muscle wasting. TGF-β–activated kinase 1 (TAK1) is an important signaling protein that regulates cell survival, growth, and inflammation. TAK1 has been recently found to promote myofiber growth in the skeletal muscle of adult mice. However, the role of TAK1 in muscle diseases remains poorly understood. In the present study, we have investigated how TAK1 affects the progression of dystrophic phenotype in the mdx mouse model of Duchenne muscular dystrophy (DMD). TAK1 is highly activated in the dystrophic muscle of mdx mice during the peak necrotic phase. While targeted inducible inactivation of TAK1 inhibits myofiber injury in young mdx mice, it results in reduced muscle mass and contractile function. TAK1 inactivation also causes loss of muscle mass in adult mdx mice. By contrast, forced activation of TAK1 through overexpression of TAK1 and TAB1 induces myofiber growth without having any deleterious effect on muscle histopathology. Collectively, our results suggest that TAK1 is a positive regulator of skeletal muscle mass and that targeted regulation of TAK1 can suppress myonecrosis and ameliorate disease progression in DMD.

Authors

Anirban Roy, Tatiana E. Koike, Aniket S. Joshi, Meiricris Tomaz da Silva, Kavya Mathukumalli, Mingfu Wu, Ashok Kumar

×

Figure 1

Activation of TAK1 in skeletal muscle of mdx mice.

Options: View larger image (or click on image) Download as PowerPoint
Activation of TAK1 in skeletal muscle of mdx mice.
(A) Western blot show...
(A) Western blot showing protein levels of p-TAK1 and total TAK1 in GA muscle of 4- and 16-week-old WT and mdx mice. (B and C) Quantification of protein levels of p-TAK1 and total TAK1 in (B) 4-week and (C) 16-week-old WT and mdx mice. n = 3 mice per group. Data represented as mean ± SEM. *P ≤ 0.05, values significantly different from GA muscle of corresponding age-matched WT mice by unpaired Student t test. (D) Transverse sections of TA muscle from 2-, 4-, 6-, and 8-week-old mdx mice stained with H&E. Scale bar: 100 μm. (E and F) Western blot and densitometry analysis showing protein levels of TAK1, p-RIPK1 (S321), and total RIPK1 in GA muscle of mdx mice at indicated age. n = 3–5. #P ≤ 0.05, values significantly different from GA muscle of 2-week-old mdx mice by 1-way ANOVA followed by Tukey’s multiple-comparison test. (G) Representative images of TA muscle sections from 4-week-old mdx mice after immunostaining for TAK1 and Pax7 protein. Nuclei was counterstained with DAPI. Scale bar: 50 μm. Blue arrows point to Pax7+ satellite cells. White arrows point to myonuclei. n = 3–4.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts